Recent advances on polaprezinc for medical use (Review)

• Published in: Experimental and therapeutic medicine Vol. 22; no. 6
• Main Authors: Li, Mingru, Sun, Zhen, Zhang, Hong, Liu, Zhaoyang
• Format: Journal Article
• Language: English
• Published: Spandidos Publications 01-12-2021; D.A. Spandidos
• Subjects: Antiulcer drugs; Carnosine; Chemical properties; Health aspects; Review; Zinc compounds; Japan
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2021.10880

The present study described the chemical and biological properties of zinc complex of L-carnosine (L-CAZ; generic name, polaprezinc; chemical name, catena-(S)-[[micro]-[N( [alpha])-(3-aminopropionyl) histidinato (2-) N1, N2, O: N(x)]-zinc], molecular formula, [C.sub.9][H.sub.14][N.sub.4][O.sub.3]Zn; molecular weight, 291.6404; CAS registry number, 107667-60-7). Characterized as a white or yellowish white crystalline powder, this drug is insoluble in glacial acetic acid and almost insoluble in water, methanol, ethanol and ether. It is soluble in dilute hydrochloric acid, dilute nitric acid and sodium hydroxide solution, and its melting point is 260-270[degrees]C. Polaprezinc is an anti-ulcer drug that was jointly studied and developed by Hamari Chemicals Co., Ltd. and Zeria Pharmaceutical Co., Ltd., and was first approved in Japan in 1994. This review article summarizes the research advances of polaprezinc, including the patents, preparations, synthetic routes, pharmacokinetics, pharmacological effects and application in clinical research. Key words: polaprezinc, membrane protection, Helicobacter pylori, antioxidant, anti-apoptosis